Evolution of symptoms with CAS + IMD
sore throat, nausea, loss of taste/smell, diarrhea, fatigue, chest pain, vomiting, dizziness, cough, headache, chills, aches, shortness of breath
SORE THROAT, LOSS OF APPETITE
The treatment effect on symptom trajectories estimated through the two-step approach is plotted in Fig. Treatment effect trajectories for patients enrolled in the adaptive Phase I/II/III CAS + IMD clinical trial. Treatment effect trajectories for each symptom of the Symptoms Evolution of COVID-19 instrument were obtained using a two-step approach (see Statistical Methodology for more details). The curve estimate is indicated by the blue line in the center, and 95% confidence bands are indicated by the red lines. The symptoms with significant treatment effects are highlighted in red boxes (upper bounds of the confidence bands below 0 for at least 2 consecutive days). The symptoms are ranked by area under the curve for the treatment effect trajectories relative to horizontal line y = 0.0%. Hierarchical clustering suggested that the 17 symptoms with significant treatment effects could be grouped into three clusters based on onset of treatment response (Supplemental Fig. Treatment effect trajectories by symptom clusters. Hierarchical clustering was performed to group symptoms with similar treatment trajectories over time. Cluster 1 (early response) included headache, diarrhea, vomiting, feeling feverish, body aches, and chills; cluster 2 (mid-cycle of the 15-day observation) included pressure/tightness in chest, chest pain, loss of appetite, nausea, fatigue, and dizziness; and cluster 3 (delayed response) included cough, sputum/phlegm, sore throat, loss of taste/smell, and shortness of breath. An optimal number of clusters was determined using gap statistics.